Phendimetrazine

From Wikipedia, the free encyclopedia


Phendimetrazine
Systematic (IUPAC) name
3,4-Dimethyl-2-phenyl-morpholine
Identifiers
CAS number	634-03-7
ATC code	?
PubChem	12460
Chemical data
Formula	C₁₂H₁₇N O
Mol. mass	191.27
Pharmacokinetic data
Bioavailability	Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours
Metabolism	hepatic
Half life	19-24 hours
Excretion	Urinary elimination
Therapeutic considerations
Pregnancy cat.	C (US)
Legal status	C-III (US)
Routes	Oral

Indicated for:

obesity

Phendimetrazine (Bontril) is a weight loss medication. Phendimetrazine is a drug as potent as amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.

Phendimetrazine is used clinically in the form of phendimetrazine tartrate.

Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction.

According to the "List of psychotropic substances under international control," phendimetrazine is a Schedule IV controlled substance.^{[citation needed]}

[edit] External links

List of psychotropic substances under international control

Phendimetrazine is listed as a Schedule III substance under the U.S. Controlled Substance Act in the 2007 Drug Identification Bible, pg 615 and under Section 11056(b)(6) California Health & Safety Code.